As its accompanying editorial ([@bib0045]) perceives, Arshad's report ([@bib0005]) indeed fuels the fire of the hydroxychloroquine (HCQ) controversy. It also fans the steroid controversy ([@bib0050]).

The 2541 consecutive COVID-19 subjects included over seven weeks from 3/10/20 undoubtedly included 213 consecutive patients, starting on 3/12/20 for two weeks, in a pre/post quasi-experiment ([@bib0030]). Fadel's conclusion that *"early short course of methylprednisolone* \[MPD\] *in ... moderate to severe COVID-19 ... improved clinical outcomes"* undoubtedly informed treatment protocols for the remaining five weeks of Arshad, affirming the editorial speculation that as the Henry Ford Hospital System *"became more experienced ..., survival may have improved..."* With differences in steroid use noted in the editorial, a comparison with Fadel ([Table 1](#tbl0005){ref-type="table"} ) is intriguing:1.*A similar "control" (∼26%) mortality* (Row A) Late 70% HCQ use + late 57% steroid use, sicker (needing at least oxygen) patients= (Row C) No use HCQ + "mostly early" 36% steroid use, sicker plus less sick patients2.*A similar treatment mortality (∼13.5%):* (Row B) Early 79% HCQ use + early 68% steroid use, sicker patients= (Row D) Early 100% HCQ use + mostly early 79% steroid use, sicker plus less sick patients Table 1Comparison of related studies involving hydroxychloroquine and steroids in COVID-19.Table 1RowStudyGroupData typenHCQ\
Use%DaysHCQ + AZI\
Use %Steroid\
Use %DaysMortality % (HR)HR. CoxAFadelStandardCrude8170.43 (1--4)in HCQLate 56.85 (3--7)26.3BFadelSteroidCrude13278.81 (0--2)in HCQEarly 68.22 (1--3)13.6 (0.52)CArshadNoneCrude4090NA035.7NA26.4DArshadHCQCrude12021001 (1--2)078.9NK13.5 (0.51)0.34EArshadNone/AZIPropensity190044.2NKNK--FArshadHCQ [+]{.ul} AZIPropensity19010044.2NKNK0.487GArshadAZICrude1470NK10038.8NK22.4 (0.85)1.05HArshadHCQ/AZI (severe)Crude783100NK10074.3NK20.1 (0.76)0.294IBani-SadrStandardCrude8513.3NK012.9At SOB20--JBani-SadrSteroidCrude1726NK069.2At SOB18 (0.9)0.47[^1][^2]

With much lower HCQ usage, a similar pre/post study ([Table 1](#tbl0005){ref-type="table"} ([@bib0010])) found steroid-associated reduced mortality, but only after multivariate adjustment. These studies support the early combined in-hospital use of HCQ and MPD to reduce mortality and the need for ventilation. This contrasts with an effect of dexamethasone limited to more advanced disease ([@bib0040]), possibly reflecting between-steroid pharmacological differences ([@bib0025]). Early use of MPD is supported by other studies, some of which ([@bib0050]) also involve HCQ with possible synergy via a lysosomal mechanism ([@bib0035]). HCQ, given alone at this stage, may require zinc ([@bib0020]). In Arshad's less sick and comorbid (propensity-matched) patients, HCQ's steroid requirement appears reduced. For early post-exposure prophylaxis in young subjects ([@bib0015];[@bib0055]), HCQ requires neither zinc nor steroid.

These data support prospective evaluation of a stage- and age- nuanced approach to COVID-19 that exploits the multiple mechanisms of HCQ and synergy with MPD. Detailed stratification of observational studies involving HCQ, steroids (and heparin) is urged, as well as the conduct of prospective meta-analyses of ongoing studies to facilitate meaningful sub-group analysis.
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[^1]: NK, Not known (information not supplied in paper).

[^2]: Days, Median days (IQR) to drug use.
